Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
被引用次数：675 相关文章

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

COV-BARRIER Study Group - The Lancet Respiratory …, 2021 - scholars.okstate.edu
Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The Lancet …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
[HTML] sld.cu

[HTML][HTML] Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The Lancet …, 2021 - covid19.sld.cu
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

COV-BARRIER Study Group - The Lancet …, 2021 - providence.elsevierpure.com
Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - Lancet Respiratory …, 2021 - zora.uzh.ch
Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan… - The Lancet …, 2021 - researchworks.creighton.edu
Abstract antivirus agent baricitinib dexamethasone placebo remdesivir adenosine
phosphate alanine azetidine derivative corticosteroid purine derivative pyrazole derivative …

[引用][C] Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The Lancet Respiratory …, 2021 - cir.nii.ac.jp
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER):
a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial | CiNii Research …
[PDF] pesquisare.com.br

[PDF][PDF] Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono, CE Kartman… - Lancet, 2021 - pesquisare.com.br
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …